UCSF researchers program cells to be remote-controlled by light

September 13, 2009

UCSF researchers have genetically encoded mouse cells to respond to light, creating cells that can be trained to follow a light beam or stop on command like microscopic robots.

This is the first time researchers have been able to import a light controlled "on-off switch" from plants into a mammalian cell to instantly control a variety of cell functions, the researchers said. As such, it offers both a powerful new tool in cancer and cardiovascular research, as well as the potential to ultimately control complex processes such as nerve growth.

The findings appear in the September 13 advanced online publication of the journal "Nature" and are available at www.nature.com. They are reported alongside a paper on similar research led by Klaus Hahn, Ph.D., and his colleagues at the University of North Carolina, Chapel Hill.

Together, the papers are the first to demonstrate that plant light-switches can be imported into mammalian cells to control complex regulatory processes. The UCSF research is unique in developing a generic plug-and-play switch, based on protein recruitment, which can be wired to control diverse processes in many types of cells and organisms, the researchers said.

The findings could have various therapeutic applications down the road, such as the ability to guide nerve cells to reconnect across a broken spinal pathway in a spinal cord injury, according to Wendell Lim, PhD, one of three senior authors on the paper and the director of the Cell Propulsion Laboratory, a National Institutes of Health Nanomedicine Development Center at UCSF and UC Berkeley.

More immediately, the findings offer a new approach for scientific research into the complex regulatory processes involved in diseases like cancer and inflammation, he said.

"This is a powerful tool for cell biology and cancer research," said Lim, who is a professor in the UCSF Department of Cellular and Molecular Pharmacology. "If you have a controllable 'light switch' that is generic enough to use in multiple cell functions, it gives you the ability to control where and when a cell moves, using a simple beam of light, and control what it does when it gets there."

Many cell processes are governed by where and when proteins appear in the cell, Lim explained. When those processes are based on an extremely complex network of signals, such as in diseases like cancer, he added, it's helpful to have an on-off switch to insert into that process.

The research was carried out by Anselm Levskaya, a graduate student in both Lim's laboratory and in the laboratory of Chris Voigt, PhD, a synthetic biologist and assistant professor of pharmaceutical chemistry in the UCSF School of Pharmacy who was also a senior author on the paper.

Levskaya initially looked to plants for proteins that might serve as the light sensor. Plants are known to rely upon phytochromes, or light-sensing signaling proteins, to control a variety of processes, such as a plant's growth toward sunlight and seed germination.

He proposed that these phytochromes could be genetically engineered into mammalian cells and tied to a specific function, in this case, cell movement.

Levskaya identified a pair of interacting proteins from plants, known as the PhyB-PIF interaction, that could be turned on and off like a switch, and then imported that cellular signaling system into live mouse cells in a cellular pathway that controls cell motion. The resulting cells can be pulled by an external beam of dilute red light, or pushed away by an external infrared beam.

"We've been able to use similar light sensors to program bacteria and yeast cells to follow a chain of if-then commands," Voigt said. "What's remarkable here is the ability to, first, do this in mammalian cells, and secondly, find a method to turn them off again after they've performed the function we selected."

The reversible aspect of Levskaya's work is significant, Voigt said. While many methods are aimed at disrupting cellular pathways, most are fairly simple and only work in one direction: they shut a process down, or prevent two proteins from interacting, but they are limited to that one action.

This approach, by contrast, enables researchers to control precisely when the disruption occurs and for how long, then stop it at will.

The work involved a collaboration between three UCSF laboratories: the Voigt Laboratory, which uses synthetic biology to create light switches and sensors in bacteria; the Lim Lab, which studies how complex networks of signaling proteins cause cells to move, grow and differentiate; and the Weiner Lab, led by Orion Weiner, PhD, which uses microscopy to study guided cell movement.
All three labs are affiliated with the National Institutes of Health Nanomedicine Development Center at UCSF, known as the Cell Propulsion Laboratory, whose goal is to engineer "smart cells" that are programmed to carry out novel therapeutic functions in cancer and regenerative medicine. The labs are also affiliated with the California Institute for Quantitative Biosciences (QB3) at UCSF.

Levskaya is studying in the UCSF Graduate Program in Biophysics and in the Department of Pharmaceutical Chemistry, in the UCSF School of Pharmacy. Voigt is a faculty member of the Department of Pharmaceutical Chemistry. Weiner is in the UCSF Cardiovascular Research Institute. Lim is a member of the Department of Cellular and Molecular Pharmacology, and the Howard Hughes Medical Institute.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, please visit www.ucsf.edu.

University of California - San Francisco

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.